1cP-AL-LAD Facts
Psychedelic;
Description
1cP-AL-LAD is a synthetic psychedelic of the lysergamide class. It activates serotonin receptors in the brain, producing the visual and cognitive shifts characteristic of classical psychedelics.
Subjective effects include geometric visual patterns, brightened colors, time alteration, accelerated thinking, and elevated mood. The experience follows the classical lysergamide arc — visually rich, cognitively expansive, with a light stimulant edge, shaped heavily by mindset and environment.
1cP-AL-LAD produces no physical dependence, and serotonergic psychedelics carry an extremely high physiological safety margin;[1] rapid tolerance after a single dose makes compulsive use self-limiting.[2] The primary risks are psychological — acute distress, rare persistent visual disturbances, and psychiatric destabilisation, amplified sharply by combinations with MAOIs or lithium.
Dose and durationby route · individual sensitivity varies
Starts in 20 – 60 minLasts 7 – 10 hoursAfter-effects 2 – 18 hours
Body and dependence
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 14 days
- Carries over to
- LSD;
psilocybin; mescaline; DMT; other serotonergic psychedelics
Effectslikely at a common dose
- Perception
- Auditory enhancement;
Color alteration; Color enhancement; Environmental patterning; Geometry; Music enhancement; Tracers; Visual breathing; Visual drifting; +26 possible, including Spatial disorientation, Visual haze / noise, Vestibular distortion - Body
- Body scan awareness;
Pupil dilation; Stimulation; +24 possible, including Insomnia, Heart rate perception changes, Dizziness - Thinking
- Aesthetic enhancement;
Cognitive flexibility; Conceptual thinking; +31 possible, including Cognitive impairment, Decision impairment, Suggestibility enhancement - Feeling
- none likely · 8 possible, including Emotional lability, Anxiety, Paranoia
- Self
- none likely · 9 possible, including Derealization, Depersonalization
- Time
- Time alteration;
+3 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 5 possible
Who shouldn't take it
Combinations60 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [2]^Buckholtz NS, Zhou DF, Freedman DX, Potter WZ (1990) Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain — Neuropsychopharmacology PMID:1969270